CYTK Cytokinetics Inc

Price (delayed)

$50.17

Market cap

$4.72B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.55

Enterprise value

$4.95B

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by ...

Highlights
Cytokinetics's gross profit has soared by 162% YoY and by 132% from the previous quarter
The revenue has soared by 162% year-on-year and by 132% since the previous quarter
Cytokinetics's quick ratio has soared by 54% YoY but it has decreased by 4.3% from the previous quarter
The net income is down by 39% year-on-year but it is up by 16% since the previous quarter
The debt has increased by 36% YoY
CYTK's equity is down by 4.2% since the previous quarter

Key stats

What are the main financial stats of CYTK
Market
Shares outstanding
94.14M
Market cap
$4.72B
Enterprise value
$4.95B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
38.57
Price to sales (P/S)
28.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.77
Earnings
Revenue
$151.15M
EBIT
-$201.99M
EBITDA
-$198.05M
Free cash flow
-$236.05M
Per share
EPS
-$2.55
Free cash flow per share
-$2.75
Book value per share
$1.3
Revenue per share
$1.76
TBVPS
$9
Balance sheet
Total assets
$771.72M
Total liabilities
$660.3M
Debt
$324.05M
Equity
$111.41M
Working capital
$535.41M
Liquidity
Debt to equity
2.91
Current ratio
9.01
Quick ratio
8.8
Net debt/EBITDA
-1.16
Margins
EBITDA margin
-131%
Gross margin
100%
Net margin
-142.8%
Operating margin
-118.8%
Efficiency
Return on assets
-26.2%
Return on equity
-119.9%
Return on invested capital
-21.4%
Return on capital employed
-28.7%
Return on sales
-133.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CYTK stock price

How has the Cytokinetics stock price performed over time
Intraday
-0.26%
1 week
-6.29%
1 month
23.88%
1 year
56.05%
YTD
10.07%
QTD
27.69%

Financial performance

How have Cytokinetics's revenue and profit performed over time
Revenue
$151.15M
Gross profit
$151.15M
Operating income
-$179.64M
Net income
-$215.92M
Gross margin
100%
Net margin
-142.8%
Cytokinetics's gross profit has soared by 162% YoY and by 132% from the previous quarter
The revenue has soared by 162% year-on-year and by 132% since the previous quarter
Cytokinetics's operating margin has soared by 65% from the previous quarter and by 46% YoY
The net margin has soared by 64% from the previous quarter and by 47% YoY

Growth

What is Cytokinetics's growth rate over time

Valuation

What is Cytokinetics stock price valuation
P/E
N/A
P/B
38.57
P/S
28.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.77
The EPS has grown by 20% from the previous quarter but it has contracted by 16% YoY
The price to book (P/B) is 82% higher than the last 4 quarters average of 21.2
CYTK's equity is down by 4.2% since the previous quarter
The revenue has soared by 162% year-on-year and by 132% since the previous quarter
CYTK's P/S is 55% below its last 4 quarters average of 63.3 and 15% below its 5-year quarterly average of 33.7

Efficiency

How efficient is Cytokinetics business performance
The ROS has soared by 64% from the previous quarter and by 45% YoY
The return on equity is up by 33% year-on-year and by 27% since the previous quarter
The company's return on assets rose by 22% QoQ and by 10% YoY
CYTK's return on invested capital is up by 22% since the previous quarter and by 9% year-on-year

Dividends

What is CYTK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CYTK.

Financial health

How did Cytokinetics financials performed over time
The total assets is 17% greater than the total liabilities
Cytokinetics's quick ratio has soared by 54% YoY but it has decreased by 4.3% from the previous quarter
The company's current ratio has surged by 53% YoY but it fell by 3.4% QoQ
The debt is 191% more than the equity
Cytokinetics's debt to equity has shrunk by 80% YoY but it has increased by 5% QoQ
The debt has increased by 36% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.